MSD rose 5.79% before the market and is now at $143.00. Moderna once rose more than 50% before the market. According to the news, the individualized novel antigen therapy Intismeran Autogene, jointly developed by MSD and Moderna, used Keytruda in combination with Keytruda in the phase III melanoma trial, and will communicate with regulators about the marketing application.

MSD rose 5.79% before the market and is now at $143.00. Moderna once rose more than 50% before the market. According to the news, the individualized novel antigen therapy Intismeran Autogene, jointly developed by MSD and Moderna, used Keytruda in combination with Keytruda in the phase III melanoma trial, and will communicate with regulators about the marketing application.